<DOC>
	<DOCNO>NCT00726609</DOCNO>
	<brief_summary>The purpose postmarketing surveillance study collect extensive body data large patient population every day life investigate safety efficacy NOXAFIL® ( posaconazole ) treatment invasive fungal disease .</brief_summary>
	<brief_title>Post-marketing Surveillance Study Invasive Mycosis With Posaconazole ( Study P04641 )</brief_title>
	<detailed_description>Data regard demographic , underlie disease , prior fungal infection , prior antifungal medication , invasive fungal infection sign &amp; symptom , concomitant medication , posaconazole use , tolerability , safety therapy outcome collect abstracted electronic Case Report Forms . This surveillance study originally limited subject receive posaconazole salvage antifungal therapy indicate . A subgroup subject risk invasive fungal infection include prophylactic treatment follow enlargement market authorization NOXAFIL® ( posaconazole ) course study . These participant contribute data assessment safety .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Adult subject : Invasive aspergillosis refractory , intolerant , amphotericin B itraconazole , Fusariosis refractory , intolerant , amphotericin B , Chromoblastomycosis mycetoma refractory , intolerant , itraconazole , Coccidiomycosis refractory , intolerant , amphotericin B , itraconazole fluconazole . Subjects receive remissioninduction chemotherapy acute myelogenous leukemia ( AML ) myelodysplastic syndrome ( MDS ) expect result prolong neutropenia high risk develop invasive fungal infection . Hematopoietic stemcell transplant ( HSCT ) recipients undergo highdose immunosuppressive therapy Graftversushost disease high risk develop invasive fungal infection . Comedication participant ergotamine , dihydroergotamine , terfenadine , astemizole , cisapride , pimozide , halofantrine , chinidine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>